These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 14872476

  • 1. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, Furst DE.
    Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
    [Abstract] [Full Text] [Related]

  • 3. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
    Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Atkins KM, Feng A, Burge DJ.
    Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
    [Abstract] [Full Text] [Related]

  • 4. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 5. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study 314 Investigators.
    Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
    [Abstract] [Full Text] [Related]

  • 6. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group.
    Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.
    Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME.
    J Rheumatol; 2006 Apr; 33(4):659-64. PubMed ID: 16482646
    [Abstract] [Full Text] [Related]

  • 8. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 9. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
    Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR.
    Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
    [Abstract] [Full Text] [Related]

  • 10. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 11. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 13. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B.
    BMJ; 2010 Feb 02; 340():c147. PubMed ID: 20124563
    [Abstract] [Full Text] [Related]

  • 14. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ.
    N Engl J Med; 1999 Jan 28; 340(4):253-9. PubMed ID: 9920948
    [Abstract] [Full Text] [Related]

  • 15. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov 28; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 16. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D.
    Arthritis Rheum; 2002 Mar 28; 46(3):614-24. PubMed ID: 11920396
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
    Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA.
    J Rheumatol; 2004 Dec 28; 31(12):2356-9. PubMed ID: 15570634
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P, 20000223 Study Group.
    Arthritis Rheum; 2004 May 28; 50(5):1412-9. PubMed ID: 15146410
    [Abstract] [Full Text] [Related]

  • 19. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P.
    Arthritis Rheum; 2007 Apr 15; 57(3):448-53. PubMed ID: 17394231
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
    Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kümmerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI.
    Rheumatology (Oxford); 2009 Aug 15; 48(8):916-9. PubMed ID: 19483091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.